Trials / Completed
CompletedNCT01297322
RESPECT Trial - (Rapid Extravascular Sealing Via PercutanEous Collagen ImplanT)
A Multi-Center, Prospective, Randomized, Controlled, Trial to Evaluate the Safety and Efficacy of the Cardiva VASCADE VCS vs. Manual Compression for the Management of the Femoral Arteriotomy After Percutaneous Endovascular Procedures
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 420 (actual)
- Sponsor
- Cardiva Medical, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this trial is to demonstrate the safety and effectiveness of the Cardiva VASCADE™ Vascular Closure System (VCS) in sealing femoral arterial access sites. Hypothesis: The Cardiva VASCADE™ VCS provides times to hemostasis (TTH) and time to ambulation (TTA) results that are less than manual compression by a clinically meaningful and statistically significant margin. The rate of major access site-related complications with the Cardiva VASCADE™ VCS is non-inferior to the major complication rates of manual compression for sealing femoral arterial access sites.
Detailed description
A prospective, randomized, controlled multi-center clinical trial designed to evaluate the safety and effectiveness of the study device in sealing femoral arterial access sites and providing reduced times to hemostasis and ambulation compared with manual compression at the completion of diagnostic or interventional endovascular procedures performed through 6 Fr or 7 Fr introducer sheaths. Subjects will be randomized in a 2:1 treatment device to control ratio.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Manual compression | Standard of Care |
| DEVICE | Cardiva VASCADE™ Vascular Closure System | Investigational Hemostatic Vascular Closure System |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2012-06-01
- Completion
- 2012-07-01
- First posted
- 2011-02-16
- Last updated
- 2020-01-22
- Results posted
- 2014-10-03
Locations
21 sites across 2 countries: United States, Australia
Source: ClinicalTrials.gov record NCT01297322. Inclusion in this directory is not an endorsement.